Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major lung adenocarcinoma markets reached a value of US$ 14.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 27.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.23% during 2024-2034.


The lung adenocarcinoma market has been comprehensively analyzed in IMARC's new report titled "Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lung adenocarcinoma refers to a type of non-small cell lung cancer that originates in the glandular cells lining the air sacs (alveoli) in the lungs. This disease usually tends to grow slowly, but over time it often spreads to other parts of the body, such as the lymph nodes, liver, bones, or brain. The symptoms of lung adenocarcinoma can vary from person to person, and some patients may not develop any indications in the early stages. However, as the tumor grows and spreads, individuals suffering from the illness may experience persistent coughing, fatigue, shortness of breath, chest pain, unexplained weight loss, coughing up blood, lack of appetite, hoarseness or voice changes, recurrent respiratory infections, etc. The diagnosis of this condition typically requires a combination of medical history evaluation, characteristic findings, and a physical examination. Several diagnostic techniques, such as X-rays, positron emission tomography scans, magnetic resonance imaging, etc., may be adopted to visualize the lungs and identify any abnormal growths or masses. In some cases, a tissue biopsy is also performed to confirm the diagnosis among patients.

The increasing incidence of smoking tobacco, including cigarettes, pipes, and cigars, which can damage the lung tissue and create an environment that promotes the growth of cancerous cells, is primarily driving the lung adenocarcinoma market. In addition to this, the rising cases of germline variations in genes that are involved in DNA repair mechanisms and tumor suppression are also creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive radiofrequency ablation technique, which uses thermal energy to destroy cancerous cells and causes less trauma to the surrounding healthy tissue as compared to open surgeries, is further bolstering the market growth. Apart from this, the inflating application of targeted therapies, like tyrosine kinase inhibitors, owing to their various associated advantages, such as improved efficacy, long-term disease control, increased treatment outcomes, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which aims to treat the ailment by modifying or replacing defective genetic material with functional ones, is expected to drive the lung adenocarcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the lung adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lung adenocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lung adenocarcinoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lung adenocarcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lung adenocarcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lung adenocarcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the lung adenocarcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lung adenocarcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lung adenocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of lung adenocarcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of lung adenocarcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of lung adenocarcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with lung adenocarcinoma across the seven major markets?
What is the size of the lung adenocarcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lung adenocarcinoma?
What will be the growth rate of patients across the seven major markets?

Lung Adenocarcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lung adenocarcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lung adenocarcinoma market?
What are the key regulatory events related to the lung adenocarcinoma market?
What is the structure of clinical trial landscape by status related to the lung adenocarcinoma market?
What is the structure of clinical trial landscape by phase related to the lung adenocarcinoma market?
What is the structure of clinical trial landscape by route of administration related to the lung adenocarcinoma market?